Abstracts tagged "glucocorticoids"

Abstract Number: 0895 • ACR Convergence 2025
Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial
FRANK BUTTGEREIT¹, Kevin Winthrop², Leonard Calabrese³, Ivan Lagunes⁴, Aditi Kadakia⁵, Ana Romero⁶, Shaofei Zhao⁴, Weihan Zhao⁴, Arathi Setty⁴ and Jeffrey Curtis⁷, ¹Charité University Medicine Berlin, Berlin, Berlin, Germany, ²Oregon Health & Science University, Portland, OR, ³Cleveland Clinic, Cleveland, OH, ⁴Abbvie Inc, North Chicago, IL, ⁵AbbVie Inc, Woburn, MA, ⁶AbbVie, Barcelona, Spain, ⁷University of Alabama at Birmingham, Birmingham
Background/Purpose: This study assessed the occurrence of adverse events of serious infections, herpes zoster, and opportunistic infection during concomitant treatment with GCs and after GC…
Abstract Number: 0360 • ACR Convergence 2025
Assessing Content Validity of a New Questionnaire Evaluating Glucocorticoid Toxicity
Timothy Howell¹, anne Skalicky², Louis Matza¹, John Stone³, Martha Stone⁴, Vijayaraghava Rao⁵ and Glenn Phillips⁵, ¹evidera, Washington, DC, ²evidera, Seattle, WA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Steritas, LLC, Concord, MA, ⁵argenx, Boston, MA
Background/Purpose: While glucocorticoids (GCs) are commonly used to treat a range of inflammatory diseases, the burden of toxicities associated with these medications is significant. The…
Abstract Number: 1629 • ACR Convergence 2025
Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica
Sebastian E Sattui¹, Christian Dejaco², Kerri Ford³, Stefano Fiore⁴, Sebastian H Unizony⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ³Sanofi, Cambridge, MA, ⁴Sanofi, Morristown, NJ, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶The University of Alabama at Birmingham, Birmingham, AL, ⁷Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: A previous post hoc analysis of frail (defined by claims-based frailty index [CFI] ≥0.2) patients with PMR on second line (2L) and 3L treatment…
Abstract Number: 0668 • ACR Convergence 2025
Glucocorticoid-Sparing Effects and Flare Suppression: Metformin Versus SGLT2 Inhibitors in Systemic Lupus Erythematosus
Takeshi Suzuki, Yoshiki Ishizaki, Takayasu Ando, Shotaro Suzuki, Keiichi Sakurai, Kumiko Tonooka, Yukiko Takakuwa, Hiroko Nagafuchi, Seido Ooka and Kimito Kawahata, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Background/Purpose: While both metformin (MET) and SGLT2 inhibitors (SGLT2i) have potential immunomodulatory effects in Systemic Lupus Erythematosus (SLE), their comparative efficacy in glucocorticoid (GC)-sparing remains…
Abstract Number: 0349 • ACR Convergence 2025
Underrecognized Glucocorticoid-Induced Osteoporosis in a Polymyalgia Rheumatica Patient Cohort
katherine Loomba¹, Emily Campbell¹, Nisha Khubchandani¹, chih Fang¹, William Rigby² and Vivekanand Tiwari¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth-Hitchcock, Norwich, VT
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are systemic inflammatory disorders treated with prolonged corticosteroid therapy. Prolonged use of corticosteroids is a significant…
Abstract Number: 1610 • ACR Convergence 2025
Early Mepolizumab Initiation Enables High Glucocorticoid and Immunosuppressant Discontinuation Rates in EGPA: A Retrospective Cohort Study of 35 Patients
Takashi Yamane¹, Ayaka Inoue², Noriaki Yasuda², Takahisa Ohnishi³ and Akira Hashiramoto⁴, ¹Kakogawa Central City Hospital, Kobe, Hyogo, Japan, ²Kakogawa Central City Hospital, Kakogawa, Japan, ³Kakogawa Central City Hospital, Kobe, Japan, ⁴Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: Mepolizumab (MPZ), an anti–interleukin-5 monoclonal antibody, has shown efficacy in reducing glucocorticoid (GC) dosage and sustaining remission in eosinophilic granulomatosis with polyangiitis (EGPA). This…
Abstract Number: 0650 • ACR Convergence 2025
Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Brad Rovin¹, Jay Garg², Richard Furie³, Rachel Jones⁴, Amit Saxena⁵, Pasquale Esposito⁶, Elsa Martins⁷, Claire Petry⁷, Nicolas Frey⁷, Bongin Yoo², Imran Hassan⁸, Thomas Schindler⁷, Theodore Omachi⁹, William Pendergraft², Mittermayer Santiago¹⁰, Gustavo Aroca Martínez¹¹ and Ana Malvar¹², ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁵Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁶Clinica Nefrologica, Dialisi, Trapianto, Department of Internal Medicine, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁹Genentech, Inc., South San Francisco, ¹⁰Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Bahia, Brazil, ¹¹Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, ¹²Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: The Phase III REGENCY study (NCT04221477) demonstrated superiority of obinutuzumab (OBI) over placebo (PBO) in achieving complete renal response (CRR) at Week 76 when…
Abstract Number: 0344 • ACR Convergence 2025
Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention
Gregory Challener¹, Zandra E. Walton¹, Christine M. Parsons¹, Aakash V. Patel², Alex Tinianow³, Molly E. Griffin¹, Raisa Lomanto Silva³, Avira Som¹, Laura J. Yockey⁴, WuQiang Fan⁵, Sheila L. Arvikar¹ and Marcy Bolster⁶, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴MGH, Charlestown, MA, ⁵Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston, ⁶Massachusetts General Hospital, Concord, MA
Background/Purpose: Glucocorticoids are widely used in rheumatology and are associated with increased fracture risk. The 2022 ACR Guideline for the Prevention and Treatment of Glucocorticoid-induced…
Abstract Number: 1607 • ACR Convergence 2025
Antibiotic Prophylaxis during Treatment of ANCA-associated Vasculitis with Rituximab: Data from a Multicenter Cohort
Natasha Le Blanc¹, Lillian Barra², Sasha Bernatsky³, Alison Clifford⁴, Mojtaba Dabaghjamanesh⁵, Natasha Dehghan⁶, Aurore Fifi-Mah⁷, Jean-Paul Makhzoum⁸, Nataliya Milman⁹, Medha Soowamber¹⁰, Nader Khalidi¹¹, Christian Pagnoux¹⁰, Rosalie-Selene Meunier¹², Jan Willem Cohen Tervaert⁴, Elaine Yacyshyn⁴ and Arielle Mendel¹³, ¹McGill University, Montreal, Canada, ²Western University, London, ON, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Self employed, Richmond Hill, ON, Canada, ⁶University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Universite de Montreal, Montreal, Canada, ⁹the Ottawa Hospital, Ottawa, ON, Canada, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹McMaster University, Hamilton, ON, Canada, ¹²Hopital du Sacre-Coeur-de-Montreal, Montreal, QC, Canada, ¹³McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Antibiotic prophylaxis is recommended during initial treatment of ANCA-associated vasculitis (AAV). We assessed characteristics associated with prophylaxis within a Canadian multicenter AAV cohort starting…
Abstract Number: 0803 • ACR Convergence 2025
Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials
Mariele Gatto¹, Karen H. Costenbader², Andreas Schwarting³, Julia Harris⁴, Ciara O'Shea⁵, Roger A. Levy⁶ and Andrea Doria⁷, ¹Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, Mauriziano Hospital, Turin, Italy, ²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ³Johannes Gutenberg University Mainz, University Medical Centre, Mainz, Germany, ⁴GSK, Biostatistics, London, United Kingdom, ⁵Global Medical Affairs, GSK, Dublin, Ireland, ⁶GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁷University of Padova, Padova, Italy
Background/Purpose: Chronic GC and IS use increases damage accrual and mortality. The 2023 EULAR SLE recommendations support initiation of biologics such as BEL, a human…
Abstract Number: 0340 • ACR Convergence 2025
Associations with fragility fractures in a population with inflammatory bowel disease (IBD): An observational study.
Chern Lee Choy¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe Bay NHS Foundation Trust, Barrow-In-Furness, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: It is well recognized that inflammatory bowel disease (IBD) is associated with osteoporosis and fragility fractures, likely due to multiple factors, including systemic inflammation,…
Abstract Number: 2699 • ACR Convergence 2025
Cutaneous IgA Vasculitis: Emulation of a Target Trial from a European Multicentric Retrospective Study
Elena Biancamaria Mariotti¹, Boris Sorin², William Lutz³, Chloé Grolleau³, Thomas Bettuzzi⁴, Caterina Ricordi⁵, Santos Castañeda⁶, Luisa Herda⁷, Cord Sunderkotter⁷, Rodérau Outh⁸, Romain Paule⁹, Alexandra Audemard-Verger¹⁰, Marzia Caproni¹¹, Angelo Valerio Marzano¹², Pietro Quaglino¹³, Laura Atzori¹⁴, Julien Campagne¹⁵, Mehemt Erkan¹⁶, Nabil Belfeki¹⁷, Marijan Frkovic¹⁸, Nicolas Dupin¹⁹, Raphael Porcher²⁰, Marie Jachiet²¹ and Benjamin Terrier¹⁹, ¹University of Florence, Azienda USL Toscana Centro, Department of Dermatology, Florence, Firenze, Italy, ²Assistance Publique Hôpitaux de Paris, Paris, France, ³University Paris Cité, Hospital Saint Louis, Dermatology department, Paris, Paris, France, ⁴Université Paris Est Créteil Val de Marne, Hôpital Henri-Mondor (APHP), Service de dermatologie, EpiDermE, Paris, France, ⁵AUSL-IRCCS Reggio Emilia, Parma, Italy, ⁶Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁷Department of Dermatology and Venereology, Martin Luther University Halle-Wittenberg, Halle (Saale), Halle, Germany, ⁸Department of Internal Medicine, Centre Hospitalier de Perpignan, Perpignan, France., Clermont-Ferrand, France, ⁹Hospital Foch, Service de medicine interne, Suresnes, Paris, Suresnes, France, ¹⁰Department of Internal Medicine, Tours University Hospital, Tours, France., Tours, France, ¹¹University of Florence, Azienda USL Toscana Centro, Department of Dermatology, Florence, Florence, Italy, ¹²Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Milan, Italy, ¹³University of Turin, Department of Medical Sciences, Section of Dermatology, Turin, Torino, Italy, ¹⁴Dermatology Clinic, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Cagliari, Italy, ¹⁵Hospital Robert Schuman, Metz, France, ¹⁶Hacettepe University Faculty of Medicine Department of Pediatric Rheumatology Ankara, Türkiye, Ankara, Turkey, ¹⁷Head of the Internal Medicine and Clinical Immunology Department South Île de France Health Hospital Group, Melun Center, Melun, France, ¹⁸Division for clinical immunology and rheumatology, Department of pediatrics UHC Zagreb / School of Medicine Zagreb Croatia, Zagabria, Croatia, ¹⁹Cochin Hospital, Paris, France, ²⁰Université Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), Paris, France, Paris, France, ²¹University Paris Cité, Hôpital Saint-Louis, Dermatology department, Paris, Paris, France
Background/Purpose: Immunoglobulin A vasculitis (IgAV) is a small vessel vasculitis marked by IgA, deposition, palpable purpura with lower body predilection and variable joints, kidney and…
Abstract Number: 1598 • ACR Convergence 2025
Use of JAK Inhibitors in Medium- and Small-Sized Vasculitides: a Retrospective Multicenter Study
caterina ricordi¹, elena treppo², Pavel Novikov³, Paul Russo⁴, Luca moroni⁵, Angelo Fassio⁶, Paolo Delvino⁷, hervé lobbes⁸, Chiara Marvisi¹, Francesco Muratore¹, Xavier Puéchal⁹, Carlo Salvarani¹ and Benjamin Terrier¹⁰, ¹Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ²Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ³Sechenov University, Moscow, Russia, ⁴Royal Adelaide Hospital, Clinical Immunology and Allergy, Adelaide, Australia, ⁵IRCCS San Raffaele, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milan, Italy, ⁶University of Verona, Department of Medicine, Unit of Rheumatology, Verona, Italy, ⁷University of Milano-Bicocca, Monza, Monza and Brianza, Italy, ⁸Department of Internal Medicine, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France, ⁹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ¹⁰Cochin Hospital, Paris, France
Background/Purpose: Medium- and small-vessel vasculitides (MVV and SVV) are a heterogeneous group of inflammatory diseases affecting the vascular wall. Current treatment strategies are based on…
Abstract Number: 0792 • ACR Convergence 2025
Real-World Assessment of Glucocorticoid-Induced Skin Toxicity in Individuals with Rheumatic Diseases
Tania Chiha¹, Jiaqi Wang², Isha Jha³, Grace McMahon³, John Stone⁴ and Naomi Patel³, ¹Mount Auburn Hospital, Boston, MA, ²Massachusetts General Hospital, BOston, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital , Harvard Medical School, Concord, MA

Background/Purpose: Glucocorticoids (GC) are used to treat various inflammatory and autoimmune diseases, though despite widespread use, real-world data on skin-specific GC toxicity are limited. To…
Abstract Number: 0338 • ACR Convergence 2025
Fractures and Changes in Bone Mineral Density During Two Years of Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis: A Systematic Literature Review and Individual Participant Data Meta-Analysis
Andriko Palmowski¹, Tobias Haugegaard², Ingiäld Hafstörm³, Henning Bliddal⁴, Judith Oldenkott⁵, Siegfried Wassenberg⁶, Ernest Choy⁷, John Kirwan⁸, Robin Christensen⁹, Maarten Boers¹⁰ and FRANK BUTTGEREIT¹¹, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²The Parker Institute, Kopenhagen, Denmark, ³Karolinska Institutet, Stockholm, Sweden, ⁴The Parker Institute, Frederiksberg, Denmark, ⁵Charité, Berlin, Germany, ⁶Rheumazentrum Ratingen, Ratingen, Germany, ⁷Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁸University of Bristol, Bristol, United Kingdom, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Hovedstaden, Denmark, ¹⁰Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ¹¹Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: It is unclear to what extent low dose glucocorticoids (GCs) impact bone health in patients with rheumatoid arthritis (RA). RA leads to bone loss…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].